10 mg · 20 mg · 30 mg · 50 mg
Retatrutide
Investigational peptide targeting GIP, GLP-1 and glucagon receptors. Studied in clinical trials on body weight and glycemic control.
For research use only
Tesamorelin
GHRH analog studied in GH/IGF-1 signaling and visceral fat, including trials in people with HIV and altered fat distribution.
- Pay by card (Stripe) or Zelle
- Ships within the U.S. with tracking
- Questions? Call or email us
Benefits under study
Clinical studies in people with HIV and altered body fat distribution.
- Visceral fat reduction
- Changes in liver fat
- Regulation of the GH / IGF-1 axis
Research overview
Tesamorelin is a synthetic analog of growth hormone–releasing hormone (GHRH). It stimulates the pituitary release of growth hormone, and its downstream effects on IGF-1 have been characterized in clinical research.
It has been studied in endocrine research, GH and IGF-1 signaling, lipid metabolism and body composition. Most published trials involve people with HIV and abdominal fat accumulation, measuring visceral adipose tissue and liver fat, including a 2024 study in people on integrase inhibitors.
Available in 10 and 20 mg vials, supplied for laboratory research.
Scientific references
Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors
AIDS, 2024 · PMID 38905488
View on PubMed
